| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 1.14% |
| NAV | ₹189.66 (29 Oct 2020) |
|---|---|
| Fund Started | 01 Jan 2013 |
| Fund Size | ₹1,434 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 10.9% |
| Lupin Ltd. | Healthcare | Equity | 9.8% |
| Cipla Ltd. | Healthcare | Equity | 9.7% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 8.3% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 7.7% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 7.0% |
| Strides Pharma Science Ltd. | Healthcare | Equity | 4.5% |
| Narayana Hrudayalaya Ltd. | Healthcare | Equity | 4.0% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | Equity | 3.3% |
| Sequent Scientific Ltd. | Healthcare | Equity | 3.2% |
SBI Healthcare Opportunities Fund Direct Plan Growth is a Equity Mutual Fund Scheme launched by SBI Mutual Fund. This scheme was made available to investors on 01 Jan 2013. Tanmaya Desai is the Current Fund Manager of SBI Healthcare Opportunities Fund Direct Plan Growth fund.The fund currently has an Asset Under Management(AUM) of ₹1,434 Cr and the Latest NAV as of 29 Oct 2020 is ₹189.66.
The SBI Healthcare Opportunities Fund Direct Plan Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. Exit load of 0.50% if redeemed within 15 days
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.